Monoacylglycerol lipase (MAGL) inhibitors are considered potential therapeutic agents for a variety of pathological conditions, including several types of cancer. Many MAGL inhibitors are reported in literature; however, most of them showed an irreversible mechanism of action, which caused important side effects. The use of reversible MAGL inhibitors has been only partially investigated so far, mainly because of the lack of compounds with good MAGL reversible inhibition properties. In this study, starting from the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone (CL6a) lead compound that showed a reversible mechanism of MAGL inhibition (Ki = 8.6 µM), we started its structural optimization and we developed a new potent and selective MAGL inhibitor (17b, Ki = 0.65 µM). Furthermore, modeling studies suggested that the binding interactions of this compound replace a structural water molecule reproducing its H-bonds in the MAGL binding site, thus identifying a new key anchoring point for the development of new MAGL inhibitors.

Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors

GRANCHI, CARLOTTA;MACCHIA, MARCO;SACCOMANNI, GIUSEPPE;MANERA, CLEMENTINA;MARTINELLI, ADRIANO;MINUTOLO, FILIPPO;TUCCINARDI, TIZIANO
2016-01-01

Abstract

Monoacylglycerol lipase (MAGL) inhibitors are considered potential therapeutic agents for a variety of pathological conditions, including several types of cancer. Many MAGL inhibitors are reported in literature; however, most of them showed an irreversible mechanism of action, which caused important side effects. The use of reversible MAGL inhibitors has been only partially investigated so far, mainly because of the lack of compounds with good MAGL reversible inhibition properties. In this study, starting from the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone (CL6a) lead compound that showed a reversible mechanism of MAGL inhibition (Ki = 8.6 µM), we started its structural optimization and we developed a new potent and selective MAGL inhibitor (17b, Ki = 0.65 µM). Furthermore, modeling studies suggested that the binding interactions of this compound replace a structural water molecule reproducing its H-bonds in the MAGL binding site, thus identifying a new key anchoring point for the development of new MAGL inhibitors.
2016
Granchi, Carlotta; Rizzolio, Flavio; Palazzolo, Stefano; Carmignani, Sara; Macchia, Marco; Saccomanni, Giuseppe; Manera, Clementina; Martinelli, Adriano; Minutolo, Filippo; Tuccinardi, Tiziano
File in questo prodotto:
File Dimensione Formato  
2016_12.pdf

solo utenti autorizzati

Descrizione: reprint
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 3.16 MB
Formato Adobe PDF
3.16 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
text.pdf

Open Access dal 23/01/2019

Descrizione: post-print
Tipologia: Documento in Post-print
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.83 MB
Formato Adobe PDF
1.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/819440
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 38
social impact